Elizabeth Garrett Ingram - Net Worth and Insider Trading
Elizabeth Garrett Ingram Net Worth
The estimated net worth of Elizabeth Garrett Ingram is at least $147,612 dollars as of 2025-04-26. Elizabeth Garrett Ingram is the Chief Marketing Officer of MannKind Corp and owns about 31,141 shares of MannKind Corp (MNKD) stock worth over $147,608. Elizabeth Garrett Ingram is also the Director of Avenue Therapeutics Inc and owns about 14 shares of Avenue Therapeutics Inc (ATXI) stock worth over $4. Details can be seen in Elizabeth Garrett Ingram's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Elizabeth Garrett Ingram has not made any transactions after 2019-09-12 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Elizabeth Garrett Ingram
Elizabeth Garrett Ingram Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Elizabeth Garrett Ingram owns 2 companies in total, including Avenue Therapeutics Inc (ATXI) , and MannKind Corp (MNKD) .
Click here to see the complete history of Elizabeth Garrett Ingram’s form 4 insider trades.
Insider Ownership Summary of Elizabeth Garrett Ingram
Ticker | Company | Transaction Date | Type of Owner |
---|---|---|---|
ATXI | Avenue Therapeutics Inc | 2019-09-12 | director |
MNKD | MannKind Corp | 2019-01-31 | Chief Marketing Officer |
Elizabeth Garrett Ingram Latest Holdings Summary
Elizabeth Garrett Ingram currently owns a total of 2 stocks. Among these stocks, Elizabeth Garrett Ingram owns 31,141 shares of MannKind Corp (MNKD) as of January 31, 2019, with a value of $147,608 and a weighting of 100%. Elizabeth Garrett Ingram also owns 14 shares of Avenue Therapeutics Inc (ATXI) as of September 12, 2019, with a value of $4 and a weighting of 0%.
Latest Holdings of Elizabeth Garrett Ingram
Ticker | Company | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
MNKD | MannKind Corp | 2019-01-31 | 31,141 | 4.74 | 147,608 |
ATXI | Avenue Therapeutics Inc | 2019-09-12 | 14 | 0.25 | 4 |
Holding Weightings of Elizabeth Garrett Ingram
Elizabeth Garrett Ingram Form 4 Trading Tracker
According to the SEC Form 4 filings, Elizabeth Garrett Ingram has made a total of 0 transactions in MannKind Corp (MNKD) over the past 5 years. The most-recent trade in MannKind Corp is the acquisition of 5,000 shares on January 31, 2019, which cost Elizabeth Garrett Ingram around $5,350.
According to the SEC Form 4 filings, Elizabeth Garrett Ingram has made a total of 0 transactions in Avenue Therapeutics Inc (ATXI) over the past 5 years. The most-recent trade in Avenue Therapeutics Inc is the acquisition of 14 shares on September 12, 2019, which cost Elizabeth Garrett Ingram around $100,320.
Insider Trading History of Elizabeth Garrett Ingram
- 1
Elizabeth Garrett Ingram Trading Performance
GuruFocus tracks the stock performance after each of Elizabeth Garrett Ingram's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Elizabeth Garrett Ingram is 15.71%. GuruFocus also compares Elizabeth Garrett Ingram's trading performance to market benchmark return within the same time period. The performance of stocks bought by Elizabeth Garrett Ingram within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Elizabeth Garrett Ingram's insider trading performs compared to the benchmark.
Performance of Elizabeth Garrett Ingram
Elizabeth Garrett Ingram Ownership Network
Ownership Network List of Elizabeth Garrett Ingram
Ownership Network Relation of Elizabeth Garrett Ingram

Elizabeth Garrett Ingram Owned Company Details
What does Avenue Therapeutics Inc do?
Who are the key executives at Avenue Therapeutics Inc?
Elizabeth Garrett Ingram is the director of Avenue Therapeutics Inc. Other key executives at Avenue Therapeutics Inc include 10 percent owner Fortress Biotech, Inc. , 10 percent owner Invagen Pharmaceuticals, Inc. , and Chief Executive Officer Alexandra Maclean .
Avenue Therapeutics Inc (ATXI) Insider Trades Summary
Over the past 18 months, Elizabeth Garrett Ingram made no insider transaction in Avenue Therapeutics Inc (ATXI). Other recent insider transactions involving Avenue Therapeutics Inc (ATXI) include a net purchase of 439 shares made by Jay D Kranzler , a net sale of 617,000 shares made by , and a net sale of 23 shares made by Neil Herskowitz .
In summary, during the past 3 months, insiders sold 0 shares of Avenue Therapeutics Inc (ATXI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 8,311 shares of Avenue Therapeutics Inc (ATXI) were sold and 500 shares were bought by its insiders, resulting in a net sale of 7,811 shares.
Avenue Therapeutics Inc (ATXI)'s detailed insider trading history can be found in Insider Trading Tracker table.
Avenue Therapeutics Inc Insider Transactions
Elizabeth Garrett Ingram Mailing Address
Above is the net worth, insider trading, and ownership report for Elizabeth Garrett Ingram. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Elizabeth Garrett Ingram's mailing address is: Westlake Village Ca 91362.